DK3560937T3 - Fremgangsmåder til fremstilling af 18f-mærkede psma-målrettede billeddannelsesmidler og diagnostiske fremgangsmåder dermed - Google Patents

Fremgangsmåder til fremstilling af 18f-mærkede psma-målrettede billeddannelsesmidler og diagnostiske fremgangsmåder dermed Download PDF

Info

Publication number
DK3560937T3
DK3560937T3 DK19179758.8T DK19179758T DK3560937T3 DK 3560937 T3 DK3560937 T3 DK 3560937T3 DK 19179758 T DK19179758 T DK 19179758T DK 3560937 T3 DK3560937 T3 DK 3560937T3
Authority
DK
Denmark
Prior art keywords
methods
making
imaging agents
labeled psma
targeting imaging
Prior art date
Application number
DK19179758.8T
Other languages
English (en)
Inventor
Clifford Berkman
Svetlana A Stekhova
Original Assignee
Cancer Targeted Tech Llc
Univ Washington State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Targeted Tech Llc, Univ Washington State filed Critical Cancer Targeted Tech Llc
Application granted granted Critical
Publication of DK3560937T3 publication Critical patent/DK3560937T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0489Phosphates or phosphonates, e.g. bone-seeking phosphonates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0402Organic compounds carboxylic acid carriers, fatty acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/22Amides of acids of phosphorus
    • C07F9/24Esteramides
    • C07F9/2404Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/22Amides of acids of phosphorus
    • C07F9/24Esteramides
    • C07F9/2404Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2416Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of cycloaliphatic alcohols
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/22Amides of acids of phosphorus
    • C07F9/24Esteramides
    • C07F9/2454Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2458Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576Six-membered rings
    • C07F9/58Pyridine rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK19179758.8T 2013-03-15 2014-03-14 Fremgangsmåder til fremstilling af 18f-mærkede psma-målrettede billeddannelsesmidler og diagnostiske fremgangsmåder dermed DK3560937T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361798108P 2013-03-15 2013-03-15
EP14721640.2A EP2970345B1 (en) 2013-03-15 2014-03-14 18f-labeled psma-targeted pet imaging agents

Publications (1)

Publication Number Publication Date
DK3560937T3 true DK3560937T3 (da) 2023-02-13

Family

ID=50639969

Family Applications (2)

Application Number Title Priority Date Filing Date
DK19179758.8T DK3560937T3 (da) 2013-03-15 2014-03-14 Fremgangsmåder til fremstilling af 18f-mærkede psma-målrettede billeddannelsesmidler og diagnostiske fremgangsmåder dermed
DK14721640.2T DK2970345T3 (da) 2013-03-15 2014-03-14 18f-mærkede psma-targeterede pet-kontrastmidler

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK14721640.2T DK2970345T3 (da) 2013-03-15 2014-03-14 18f-mærkede psma-targeterede pet-kontrastmidler

Country Status (16)

Country Link
US (2) US11554183B2 (da)
EP (3) EP2970345B1 (da)
CN (2) CN108558939B (da)
AU (2) AU2014228233B2 (da)
CA (1) CA2903131C (da)
DK (2) DK3560937T3 (da)
ES (2) ES2743433T3 (da)
FI (1) FI3560937T3 (da)
HR (2) HRP20230109T1 (da)
HU (2) HUE046194T2 (da)
LT (2) LT2970345T (da)
PL (2) PL2970345T3 (da)
PT (2) PT3560937T (da)
RS (1) RS64011B1 (da)
SI (2) SI2970345T1 (da)
WO (1) WO2014143736A1 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11078166B2 (en) 2015-08-13 2021-08-03 The Johns Hopkins University Triazole conjugated ureas, thioureas, carbamates, and reversed carbamates for PSMA-targeted imaging agents and uses thereof
WO2018031809A1 (en) * 2016-08-10 2018-02-15 Cancer Targeted Technology Llc Chelated psma inhibitors
EP3600024A4 (en) 2017-03-22 2021-01-06 SafeOp Surgical, Inc. MEDICAL SYSTEMS AND METHODS FOR DETECTION OF CHANGES IN ELECTROPHYSIOLOGICALLY AVOID POTENTIALS
WO2018233798A1 (en) 2017-06-20 2018-12-27 ITM Isotopen Technologien München AG NOVEL PSMA BINDING AGENTS AND USE THEREOF
CA3060143A1 (en) 2017-05-24 2018-11-29 Itm Isotopen Technologien Munchen Ag Novel psma-binding agents and uses thereof
WO2020108753A1 (en) 2018-11-28 2020-06-04 ITM Isotopen Technologien München AG Novel tumor antigen binding agents and uses thereof
WO2020224780A1 (en) 2019-05-08 2020-11-12 ITM Isotopen Technologien München AG Para-aminohippuric acid (pah) as a renal protective substance
WO2021046233A1 (en) 2019-09-03 2021-03-11 Cancer Targeted Technology Llc Chelate-containing psma inhibitors
WO2022096103A1 (en) 2020-11-05 2022-05-12 ITM Isotopen Technologien München AG Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer
WO2022111800A1 (en) 2020-11-25 2022-06-02 Itm Solucin Gmbh Stable formulations for radionuclide complexes
IL307381A (en) 2021-04-02 2023-11-01 Advanced Accelerator Applications Diagnostic methods of prostate cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1999136B1 (en) 2006-03-14 2012-10-24 Cancer Targeted Technology LLC Peptidomimetic inhibitors of psma,compounds comprising them, and methods of use
EP2063918B1 (en) * 2006-09-08 2014-02-26 Piramal Imaging SA Compounds and methods for 18f labeled agents
CN113563262A (zh) * 2008-08-01 2021-10-29 约翰.霍普金斯大学 Psma-结合剂及其用途
US9328129B2 (en) * 2010-11-12 2016-05-03 Washington State University Peptidomimetic inhibitors of PSMA
CN107325127B (zh) * 2011-06-15 2020-09-01 癌靶技术有限责任公司 螯合的psma抑制剂
CN102757296B (zh) * 2012-04-10 2014-11-19 中国科学院上海应用物理研究所 一种对化合物进行[18f]标记的方法
WO2013173583A1 (en) * 2012-05-16 2013-11-21 Cancer Targeted Technology, Llc Psma inhibitors
WO2013173630A1 (en) * 2012-05-16 2013-11-21 Cancer Targeted Technology, Llc Formulation of radiopharmaceuticals containing multiple acidic groups

Also Published As

Publication number Publication date
PL2970345T3 (pl) 2019-12-31
EP2970345B1 (en) 2019-06-19
EP2970345A1 (en) 2016-01-20
LT2970345T (lt) 2019-09-25
US20230144322A1 (en) 2023-05-11
PT3560937T (pt) 2023-02-13
EP3560937B1 (en) 2022-12-28
RS64011B1 (sr) 2023-03-31
PT2970345T (pt) 2019-09-06
AU2014228233B2 (en) 2019-02-28
WO2014143736A1 (en) 2014-09-18
AU2019203610A1 (en) 2019-06-13
DK2970345T3 (da) 2019-08-26
FI3560937T3 (fi) 2023-02-28
US11554183B2 (en) 2023-01-17
ES2743433T3 (es) 2020-02-19
EP3560937A1 (en) 2019-10-30
CN105308056B (zh) 2018-03-20
LT3560937T (lt) 2023-03-27
HRP20230109T1 (hr) 2023-04-28
SI3560937T1 (sl) 2023-04-28
HUE061402T2 (hu) 2023-06-28
CA2903131C (en) 2021-11-23
SI2970345T1 (sl) 2019-11-29
US20160030605A1 (en) 2016-02-04
HRP20191482T1 (hr) 2019-11-15
EP4180438A1 (en) 2023-05-17
PL3560937T3 (pl) 2023-03-27
AU2019203610B2 (en) 2021-02-04
CN108558939A (zh) 2018-09-21
CN105308056A (zh) 2016-02-03
AU2014228233A1 (en) 2015-09-17
CA2903131A1 (en) 2014-09-18
ES2937955T3 (es) 2023-04-03
CN108558939B (zh) 2021-08-24
HUE046194T2 (hu) 2020-02-28

Similar Documents

Publication Publication Date Title
DK3560937T3 (da) Fremgangsmåder til fremstilling af 18f-mærkede psma-målrettede billeddannelsesmidler og diagnostiske fremgangsmåder dermed
DK3090068T3 (da) Fremgangsmåde og kit til ikke-invasiv detektering af egfr-genmutationer
DK3041926T3 (da) Indretning til in-vitro-modellering af in-vivo-væv af organer
DK3022707T3 (da) Systemer og fremgangsmåder til at monitorere bevægelse af sygdomsfelt
DK3035926T3 (da) Forbindelser og fremgangsmåder til behandling af en epilepsilidelse
DK3083689T3 (da) Anti-CD3-antistoffer og fremgangsmåder til anvendelse
DK3055803T3 (da) Sporing og analyse af kliniske resultater
DK2742857T3 (da) Integration af intra-oral afbildning og volumetrisk afbildning
DK3359052T3 (da) Indretning til opsamling af væv og fremgangsmåde til anvendelse
DK3350341T3 (da) Fremgangsmåder til diagnosticering og evaluering af non-alkoholisk steatohepatitis
DK3019200T3 (da) Oligonukleotid-ligand-konjugater og fremgangsmåde til fremstiling deraf
DK3363805T3 (da) Fremgangsmåder til syntese af sphingomyeliner og dihydrosphingomyeliner
DK3008168T3 (da) Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf
DK3087095T3 (da) FcRn-antagonist og fremgangsmåder til anvendelse
DK3347016T3 (da) Diagnosticering og behandling af angstlidelse
DK3089707T3 (da) Vævtransplantater og fremgangsmåder til fremstilling og brug af samme
DK3007695T3 (da) Sammensætninger og fremgangsmåder til behandling af anæmi
DK2981541T3 (da) Syntese og anvendelse af isotopmærkede glycaner
DK3079719T3 (da) ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf
DK3117030T3 (da) Diagnosticering af sepsis
DK3209696T3 (da) Fremgangsmåder og sammensætninger til diagnosticering og behandling af glioblastom
DK3050883T3 (da) Fremgangsmåde til fremstilling af diazabicyclooctanderivater og mellemprodukter
DK3238707T3 (da) Sammensætninger og fremgangsmåder til behandling af intestinal hyperpermeabilitet
DK3044315T3 (da) Nukleinsyrer og fremgangsmåder til behandling af pompes sygdom
DK3123381T3 (da) Sammensætninger og fremgangsmåder relateret til diagnose af prostatacancer